Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review (Q36194119)

12 August 2017

1 reference

title

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

Carlson LA

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Journal of Internal Medicine

12 August 2017

published in

1 reference

12 August 2017

volume

258

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

94-114

1 reference

Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress, and their modification by nicotinic acid

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Metabolic effects of nicotinic acid in acute insulin deficiency in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2796.2005.01528.X

10.1111/J.1365-2796.2005.01528.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference